Jazz Pharmaceuticals plc
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $4.3B
- Net income
- -$356.1M
- Total assets
- $11.7B
- Market cap
- $15.0B
- Operating margin
- 17.6%
- Net margin
- 13.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $4.1B
- Operating expenses
- $3.4B
- Operating income
- $716.6M
- Income tax
- -$91.4M
- Net income
- $560.1M
- EPS (basic)
- $9.06
- EPS (diluted)
- $8.65
Balance sheet
- Total assets
- $12.0B
- Current assets
- $4.6B
- Total liabilities
- $7.9B
- Current liabilities
- $1.0B
- Shareholders’ equity
- $4.1B
Cash flow
- Operating cash flow
- $1.4B
- Investing cash flow
- -$508.2M
- Financing cash flow
- $20.5M
- Net cash flow
- $906.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $15.0B
- P/E ratio
- 26.8
- EPS (diluted)
- $8.65
- Shares outstanding
- 64.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 1, 2007
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $356.1M in FY2025.
- Revenue grew 72% from FY2020 to FY2024.
- Trading near its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 26.8.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review Jazz Pharmaceuticals plc.
Write a review
News about Jazz Pharmaceuticals plc
News & sentiment via Polygon.io
